Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226


The Oxidative Stress-Induced miR-200c Is Upregulated in Psoriasis and Correlates with Disease Severity and Determinants of Cardiovascular Risk.

Magenta A, D'Agostino M, Sileno S, Di Vito L, Uras C, Abeni D, Martino F, Barillà F, Madonna S, Albanesi C, Napolitano M, Capogrossi MC, Melillo G.

Oxid Med Cell Longev. 2019 Dec 19;2019:8061901. doi: 10.1155/2019/8061901. eCollection 2019.


SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Pai SI, Cohen EEW, Lin D, Fountzilas G, Kim ES, Mehlhorn H, Baste N, Clayburgh D, Lipworth L, Resteghini C, Shara N, Fujii T, Zhang J, Stokes M, Wang H, Twumasi-Ankrah P, Wildsmith S, Khaliq A, Melillo G, Shire N.

J Transl Med. 2019 Dec 26;17(1):429. doi: 10.1186/s12967-019-02182-1.


Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.


Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.


Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.


Role of psoriasis on subclinical cardiovascular disease.

Di Vito L, Abeni D, Uras C, Magenta A, Ciarapica R, Capogrossi MC, Melillo G.

Minerva Med. 2018 Jun;109(3):255-258. doi: 10.23736/S0026-4806.18.05448-4. Epub 2018 Jan 11. No abstract available.


Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.


NADPH oxidase 1 supports proliferation of colon cancer cells by modulating reactive oxygen species-dependent signal transduction.

Juhasz A, Markel S, Gaur S, Liu H, Lu J, Jiang G, Wu X, Antony S, Wu Y, Melillo G, Meitzler JL, Haines DC, Butcher D, Roy K, Doroshow JH.

J Biol Chem. 2017 May 12;292(19):7866-7887. doi: 10.1074/jbc.M116.768283. Epub 2017 Mar 22.


Evaluation of a feline-specific multiplex, bead-based assay for detection of cytokines, chemokines, growth factors, and other immunologically active proteins in serum and plasma samples from cats.

Halpin RE, Saunders RS, Thompson BJ, Rohde Newgent AS, Amorim J, Melillo GN, DeClue AE.

Am J Vet Res. 2016 May;77(5):495-504. doi: 10.2460/ajvr.77.5.495.


Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α.

Shalova IN, Lim JY, Chittezhath M, Zinkernagel AS, Beasley F, Hernández-Jiménez E, Toledano V, Cubillos-Zapata C, Rapisarda A, Chen J, Duan K, Yang H, Poidinger M, Melillo G, Nizet V, Arnalich F, López-Collazo E, Biswas SK.

Immunity. 2015 Mar 17;42(3):484-98. doi: 10.1016/j.immuni.2015.02.001. Epub 2015 Mar 3.


A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.

Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA.

Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3.


HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse.

Coltella N, Percio S, Valsecchi R, Cuttano R, Guarnerio J, Ponzoni M, Pandolfi PP, Melillo G, Pattini L, Bernardi R.

EMBO Mol Med. 2014 May;6(5):640-50. doi: 10.1002/emmm.201303065.


Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.

Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.

Cancer Chemother Pharmacol. 2014 Feb;73(2):343-8. doi: 10.1007/s00280-013-2362-z. Epub 2013 Nov 30.


Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.

Jeong W, Park SR, Rapisarda A, Fer N, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.

Invest New Drugs. 2014 Apr;32(2):340-6. doi: 10.1007/s10637-013-0048-3. Epub 2013 Nov 16.


Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.

Onnis B, Fer N, Rapisarda A, Perez VS, Melillo G.

J Clin Invest. 2013 Apr;123(4):1615-29. doi: 10.1172/JCI59623. Epub 2013 Mar 15.


Intracranial hemorrhage requiring surgery in neurosurgical patients given ketorolac: a case-control study within a cohort (2001-2010).

Magni G, La Rosa I, Melillo G, Abeni D, Hernandez H, Rosa G.

Anesth Analg. 2013 Feb;116(2):443-7. doi: 10.1213/ANE.0b013e3182746eda. Epub 2013 Jan 9.


Role of the VEGF/VEGFR axis in cancer biology and therapy.

Rapisarda A, Melillo G.

Adv Cancer Res. 2012;114:237-67. doi: 10.1016/B978-0-12-386503-8.00006-5. Review.


Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.

Rapisarda A, Melillo G.

Nat Rev Clin Oncol. 2012 Apr 24;9(7):378-90. doi: 10.1038/nrclinonc.2012.64. Review.


The HIF-1α-c-Myc pathway and tumorigenesis: evading the apoptotic gate-keeper.

Fer N, Melillo G.

Cell Cycle. 2011 Oct 1;10(19):3228. doi: 10.4161/cc.10.19.17049. Epub 2011 Oct 1. No abstract available.


Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH.

Cancer Res. 2011 Sep 1;71(17):5626-34. doi: 10.1158/0008-5472.CAN-11-1227. Epub 2011 Jul 27.


HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3.

Limana F, Esposito G, D'Arcangelo D, Di Carlo A, Romani S, Melillo G, Mangoni A, Bertolami C, Pompilio G, Germani A, Capogrossi MC.

PLoS One. 2011;6(6):e19845. doi: 10.1371/journal.pone.0019845. Epub 2011 Jun 22.


Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.

Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G.

Clin Cancer Res. 2011 Aug 1;17(15):5123-31. doi: 10.1158/1078-0432.CCR-11-0682. Epub 2011 Jun 14.


Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-γ in patients with chronic heart failure.

Cappuzzello C, Di Vito L, Melchionna R, Melillo G, Silvestri L, Cesareo E, Crea F, Liuzzo G, Facchiano A, Capogrossi MC, Napolitano M.

J Transl Med. 2011 Mar 21;9:28. doi: 10.1186/1479-5876-9-28.


Hypoxia: jump-starting inflammation.

Melillo G.

Blood. 2011 Mar 3;117(9):2561-2. doi: 10.1182/blood-2010-12-324913.


Hypoxia: a double-edged sword of immunity.

Sica A, Melillo G, Varesio L.

J Mol Med (Berl). 2011 Jul;89(7):657-65. doi: 10.1007/s00109-011-0724-8. Epub 2011 Feb 19. Review.


Hypoxia potentiates glioma-mediated immunosuppression.

Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB.

PLoS One. 2011 Jan 20;6(1):e16195. doi: 10.1371/journal.pone.0016195.


Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.

Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH.

Eur J Cancer. 2011 May;47(7):997-1005. doi: 10.1016/j.ejca.2010.12.016. Epub 2011 Jan 17.


Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.

Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao L, Burger AM, Ziche M, Melillo G.

Cancer Res. 2010 Sep 1;70(17):6837-48. doi: 10.1158/0008-5472.CAN-10-1075. Epub 2010 Aug 24.


Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.

Terzuoli E, Donnini S, Giachetti A, Iñiguez MA, Fresno M, Melillo G, Ziche M.

Clin Cancer Res. 2010 Aug 15;16(16):4207-16. doi: 10.1158/1078-0432.CCR-10-0156. Epub 2010 Aug 3.


MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients.

Voellenkle C, van Rooij J, Cappuzzello C, Greco S, Arcelli D, Di Vito L, Melillo G, Rigolini R, Costa E, Crea F, Capogrossi MC, Napolitano M, Martelli F.

Physiol Genomics. 2010 Aug;42(3):420-6. doi: 10.1152/physiolgenomics.00211.2009. Epub 2010 May 18.


Altered SDF-1-mediated differentiation of bone marrow-derived endothelial progenitor cells in diabetes mellitus.

De Falco E, Avitabile D, Totta P, Straino S, Spallotta F, Cencioni C, Torella AR, Rizzi R, Porcelli D, Zacheo A, Di Vito L, Pompilio G, Napolitano M, Melillo G, Capogrossi MC, Pesce M.

J Cell Mol Med. 2009 Sep;13(9B):3405-14. doi: 10.1111/j.1582-4934.2009.00655.x.


Editorial: T cells, not "immune" from HIF.

Melillo G.

J Leukoc Biol. 2010 Mar;87(3):359-61. doi: 10.1189/jlb.1009678. No abstract available.


Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.

Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.

Eur J Cancer. 2010 Jan;46(2):340-7. doi: 10.1016/j.ejca.2009.10.026. Epub 2009 Nov 27.


Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads.

Rapisarda A, Shoemaker RH, Melillo G.

Cell Cycle. 2009 Dec 15;8(24):4040-3. Epub 2009 Dec 21.


A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.

Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH.

Cancer Chemother Pharmacol. 2010 Jan;65(2):383-9. doi: 10.1007/s00280-009-1154-y. Epub 2009 Nov 6.


Development of HIF-1 inhibitors for cancer therapy.

Onnis B, Rapisarda A, Melillo G.

J Cell Mol Med. 2009 Sep;13(9A):2780-6. doi: 10.1111/j.1582-4934.2009.00876.x. Epub 2009 Aug 8. Review.


A comparison between sevoflurane and desflurane anesthesia in patients undergoing craniotomy for supratentorial intracranial surgery.

Magni G, Rosa IL, Melillo G, Savio A, Rosa G.

Anesth Analg. 2009 Aug;109(2):567-71. doi: 10.1213/ane.0b013e3181ac1265.


Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.

Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G.

Mol Cancer Ther. 2009 Jul;8(7):1867-77. doi: 10.1158/1535-7163.MCT-09-0274. Epub 2009 Jul 7.


Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.

Klausmeyer P, Zhou Q, Scudiero DA, Uranchimeg B, Melillo G, Cardellina JH, Shoemaker RH, Chang CJ, McCloud TG.

J Nat Prod. 2009 May 22;72(5):805-12. doi: 10.1021/np8006342.


Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.

Rapisarda A, Melillo G.

Drug Resist Updat. 2009 Jun;12(3):74-80. doi: 10.1016/j.drup.2009.03.002. Epub 2009 Apr 25. Review.


Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome.

Tandle AT, Calvani M, Uranchimeg B, Zahavi D, Melillo G, Libutti SK.

Exp Cell Res. 2009 Jul 1;315(11):1850-9. doi: 10.1016/j.yexcr.2009.03.021. Epub 2009 Apr 10.


Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients.

Cappuzzello C, Napolitano M, Arcelli D, Melillo G, Melchionna R, Di Vito L, Carlini D, Silvestri L, Brugaletta S, Liuzzo G, Crea F, Capogrossi MC.

Physiol Genomics. 2009 Aug 7;38(3):233-40. doi: 10.1152/physiolgenomics.90364.2008. Epub 2009 Mar 31.


Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide.

Trisciuoglio D, Uranchimeg B, Cardellina JH, Meragelman TL, Matsunaga S, Fusetani N, Del Bufalo D, Shoemaker RH, Melillo G.

J Natl Cancer Inst. 2008 Sep 3;100(17):1233-46. doi: 10.1093/jnci/djn239. Epub 2008 Aug 26.


Separation and SAR study of HIF-1alpha inhibitory tubulosines from Alangium cf. longiflorum.

Klausmeyer P, McCloud TG, Uranchimeg B, Melillo G, Scudiero DA, Cardellina JH 2nd, Shoemaker RH.

Planta Med. 2008 Feb;74(3):258-63. doi: 10.1055/s-2008-1034315. Epub 2008 Feb 26.


Synergystic induction of HIF-1alpha transcriptional activity by hypoxia and lipopolysaccharide in macrophages.

Mi Z, Rapisarda A, Taylor L, Brooks A, Creighton-Gutteridge M, Melillo G, Varesio L.

Cell Cycle. 2008 Jan 15;7(2):232-41. Epub 2007 Oct 18.


Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells.

Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G.

Cancer Res. 2008 Jan 1;68(1):285-91. doi: 10.1158/0008-5472.CAN-07-5564.


Hypoxia-inducible factor 1 inhibitors.

Melillo G.

Methods Enzymol. 2007;435:385-402.


Early postoperative complications after intracranial surgery: comparison between total intravenous and balanced anesthesia.

Magni G, La Rosa I, Gimignani S, Melillo G, Imperiale C, Rosa G.

J Neurosurg Anesthesiol. 2007 Oct;19(4):229-34.


Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.

Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7.


Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice.

Buanne P, Di Carlo E, Caputi L, Brandolini L, Mosca M, Cattani F, Pellegrini L, Biordi L, Coletti G, Sorrentino C, Fedele G, Colotta F, Melillo G, Bertini R.

J Leukoc Biol. 2007 Nov;82(5):1239-46. Epub 2007 Jul 26.


Supplemental Content

Loading ...
Support Center